{"publication_id":"9725f21e-979b-4bf8-9bb0-9575b7741390","content_hash":"sha256:d8ac65cabf1b432d9bc5b04d44e74849230a46279c468376f7cec5c39020d5dd","nodes":[{"id":"9725f21e-979b-4bf8-9bb0-9575b7741390","type":"publication","title":"Research Synthesis: Senescence Biomarker Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: 16/17 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_2","type":"claim","text":"The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 11 adjacent clinical sources, and 2 mechanistic or model-system sources, with 48 cross-study disagreements across the evidence base."},{"id":"claim_3","type":"claim","text":"No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, muscle function and immune outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_4","type":"claim","text":"The conclusion is that senescence biomarker effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_5","type":"claim","text":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-senescence_biomarker_effects-v06-DAILY-2026-06-06T16-24-19Z-R2`."},{"id":"claim_6","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_7","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_8","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune, muscle function, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_9","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_10","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_11","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_12","type":"claim","text":"| Contextual Adjacent Evidence | n=10; claims=252 | no extracted directional signal in 10/10 sources | 7 indirect; 1 mechanistic; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_13","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_14","type":"claim","text":"10 included sources were assigned to this outcome class. Directional coding: null=10. Directness coding: indirect=7, mechanistic=1, review=2."},{"id":"claim_15","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, mechanistic=1."},{"id":"claim_16","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1."},{"id":"claim_17","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2."},{"id":"claim_18","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_19","type":"claim","text":"The curated corpus is composed entirely of observational cohort designs and reviews, with no interventional randomized controlled trials included among the 17 accepted references. This absence has important implications for causal inference: associations between senescence biomarkers and clinical outcomes such as physical function or cognitive decline may reflect reverse causation, confounding by comorbidity burden, or shared upstream drivers rather than direct senescence-mediated pathways. For example, Murray 2025 reported significant associations between fisetin supplementation and changes in senescence markers with P < 0.0001, yet the observational design cannot exclude the possibility that participants who adopted supplementation also engaged in other health-promoting behaviors. The lack of blinded, placebo-controlled trials means that effect estimates for any senolytic or senomodulatory intervention on hard clinical endpoints cannot be derived from this corpus. Moreover, no long-term mortality RCT in non-diabetic adults appears in the curated set, creating a gap in the evidence for whether reducing senescent cell burden translates into survival benefit. Clinicians evaluating the senescence biomarker literature should therefore treat all reported associations as hypothesis-generating rather than practice-changing, consistent with Ioannidis 2005 caution that surrogate endpoint associations do not guarantee hard-outcome validity."},{"id":"claim_20","type":"claim","text":"A second limitation concerns single-trial generalization risk across multiple outcome domains. Within this corpus, muscle function outcomes are supported by only two sources — Murray 2025 and Fielding 2022 — both observational cohorts conducted in community-dwelling older adults. If one of these were excluded on methodological grounds, the remaining evidence base for senescence biomarkers and physical function would consist of a single study, precluding any synthesis-level pattern recognition. Nevertheless, the immune domain still rests on two studies that enrolled distinct populations and measured different biomarker panels, limiting the reliability of any pooled effect estimate. Skeletal and bone outcomes were not addressed by any human clinical study in the corpus; Morita 2025 was a systematic review of preclinical investigations only."},{"id":"claim_21","type":"claim","text":"Finally, several clinically important endpoints were either unmeasured or only tangentially addressed within the curated corpus, reflecting a substantial mechanism-to-clinic gap. Hard endpoints such as all-cause mortality, incident disability, hospitalization, and time-to-frailty-transition were not reported in any of the 17 studies; the existing evidence instead relies on surrogate biomarkers including SA-β-gal staining, p16^INK4a expression, SASP protein panels, and circulating inflammatory cytokines. Functional endpoints such as gait speed — which carries established prognostic thresholds of 0.8 m/s for impaired mobility (Studenski 2011) and 0.6 m/s for severe frailty (Cesari 2009) — were not directly linked to senescence biomarker levels in any study. The annual age-related gait-speed decline of approximately 0.05 m/s (Bohannon 1997) suggests that even modest biomarker–function associations could have cumulative clinical significance, yet no longitudinal study in the corpus tracked both trajectories concurrently over multi-year follow-up. In sum, the corpus demonstrates that senescence biomarkers are measurable and associated with intermediate outcomes, but the evidence base does not yet establish whether modifying these biomarkers improves the outcomes that matter most to patients and clinicians."},{"id":"claim_22","type":"claim","text":"For senescence biomarker effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_23","type":"claim","text":"This synthesis maps 17 included sources on Senescence Biomarker Effects across 5 outcome classes and 48 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_24","type":"claim","text":"Across 17 curated reference papers, the evidence base for Senescence Biomarker Effects shows a context-dependent profile. Null findings dominate: contextual other, muscle function. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Senescence Biomarker Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_25","type":"claim","text":"The strongest unresolved contrast is the agreement between Silwal 2023 and Miller 2024 on contextual adjacent evidence (severity 1/5), which defines the boundary condition future studies must test rather than smooth over."},{"id":"claim_26","type":"claim","text":"Prior reviews in the corpus (Morita 2025) emphasize convergent signals on Senescence Biomarker Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"claim_27","type":"claim","text":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |"},{"id":"claim_28","type":"claim","text":"| contextual adjacent evidence | 0 | 10 | null | direct interventional hard-endpoint gap |"},{"id":"claim_29","type":"claim","text":"| P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |"},{"id":"claim_30","type":"claim","text":"| P2 | muscle function: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |"},{"id":"source_1","type":"source","study":"Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches","year":2025,"doi":"10.1111/acel.70114","url":"https://doi.org/10.1111/acel.70114","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study","year":2025,"doi":"10.1016/j.jnha.2025.100529","url":"https://doi.org/10.1016/j.jnha.2025.100529","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study","year":2022,"doi":"10.1007/s11357-022-00685-2","url":"https://doi.org/10.1007/s11357-022-00685-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"A Systematic Review of the Role of Senescent Cells in Uterine Leiomyomas: Deciphering Molecular Pathways and Exploring Therapeutic Prospects","year":2026,"doi":"10.1007/s43032-026-02075-x","url":"https://doi.org/10.1007/s43032-026-02075-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"A proteomic atlas of senescence-associated secretomes for aging biomarker development","year":2020,"doi":"10.1371/journal.pbio.3000599","url":"https://doi.org/10.1371/journal.pbio.3000599","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial","year":2025,"doi":"10.3389/fimmu.2025.1570441","url":"https://doi.org/10.3389/fimmu.2025.1570441","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_7","type":"source","study":"Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway","year":2026,"doi":"10.1080/07853890.2026.2663263","url":"https://doi.org/10.1080/07853890.2026.2663263","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_8","type":"source","study":"Circulating Inflammatory, Mitochondrial Dysfunction, and Senescence-Related Markers in Older Adults with Physical Frailty and Sarcopenia: A BIOSPHERE Exploratory Study","year":2022,"doi":"10.3390/ijms232214006","url":"https://doi.org/10.3390/ijms232214006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study","year":2026,"doi":"10.3390/ijms27104406","url":"https://doi.org/10.3390/ijms27104406","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_10","type":"source","study":"Extracellular Nicotinamide Phosphoribosyltransferase Is a Component of the Senescence-Associated Secretory Phenotype","year":2022,"doi":"10.3389/fendo.2022.935106","url":"https://doi.org/10.3389/fendo.2022.935106","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction","year":2025,"doi":"10.1111/dme.70059","url":"https://doi.org/10.1111/dme.70059","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_12","type":"source","study":"Cellular senescence in acute human infectious disease: a systematic review","year":2024,"doi":"10.3389/fragi.2024.1500741","url":"https://doi.org/10.3389/fragi.2024.1500741","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_13","type":"source","study":"Targeting cellular senescence in progenitor cells as a strategy to enhance bone regeneration by cell therapies: a systematic review of pre-clinical investigations","year":2025,"doi":"10.1186/s13287-025-04767-8","url":"https://doi.org/10.1186/s13287-025-04767-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_14","type":"source","study":"Microglial senescence contributes to female-biased neuroinflammation in the aging mouse hippocampus: implications for Alzheimer’s disease","year":2023,"doi":"10.1186/s12974-023-02870-2","url":"https://doi.org/10.1186/s12974-023-02870-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_15","type":"source","study":"Cellular Senescence in Intervertebral Disc Aging and Degeneration: Molecular Mechanisms and Potential Therapeutic Opportunities","year":2023,"doi":"10.3390/biom13040686","url":"https://doi.org/10.3390/biom13040686","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_16","type":"source","study":"Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025","year":2025,"doi":"10.3389/fmicb.2025.1623875","url":"https://doi.org/10.3389/fmicb.2025.1623875","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_17","type":"source","study":"Possible Mechanisms of Oxidative Stress-Induced Skin Cellular Senescence, Inflammation, and Cancer and the Therapeutic Potential of Plant Polyphenols","year":2023,"doi":"10.3390/ijms24043755","url":"https://doi.org/10.3390/ijms24043755","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_18","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_19","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_20","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_21","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_22","type":"source","study":"Studenski 2011","year":null,"doi":"10.1001/jama.2010.1923","url":"https://doi.org/10.1001/jama.2010.1923","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_23","type":"source","study":"Cesari 2009","year":null,"doi":"10.1093/gerona/glp012","url":"https://doi.org/10.1093/gerona/glp012","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_24","type":"source","study":"Bohannon 1997","year":null,"doi":"10.1093/ageing/26.1.15","url":"https://doi.org/10.1093/ageing/26.1.15","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_25","type":"source","study":"Ioannidis 2005","year":null,"doi":"10.1371/journal.pmed.0020124","url":"https://doi.org/10.1371/journal.pmed.0020124","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_1","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_2","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_3","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_4","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_5","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_6","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_7","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_8","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_9","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_10","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_11","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_12","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_13","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_14","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_15","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_16","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_17","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_18","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_19","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_20","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_21","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_22","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_23","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_24","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_25","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_26","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_27","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_28","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_29","type":"contains_claim"},{"from":"9725f21e-979b-4bf8-9bb0-9575b7741390","to":"claim_30","type":"contains_claim"}],"screening":{"identified":17,"screened":17,"excluded":0,"included":17,"included_or_retained":17,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"17 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}